HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.

Abstract
Three new prodrugs, [prodrug 1: 4-[bis(2-iodoethyl)amino]-phenyloxycarbonyl-L-glutamic acid; prodrug 2: 3-fluoro-4-[bis(2-chlorethyl)amino]benzoyl-L-glutamic acid; and prodrug 3: 3,5-difluoro-4-[bis(2-iodoethyl)amino]benzoyl-L-glutamic acid] have been assessed for use with a mutant of carboxypeptidase G2 (CPG2, glutamate carboxypeptidase, EC 3.4.17.11,) engineered to be tethered to the outer tumor cell surface (stCPG2(Q)3) as the activating enzyme in suicide gene therapy systems. All three of the prodrugs produce much greater cytotoxicity differentials between stCPG2(Q)3- and control beta-galactosidase (beta-gal)-expressing breast carcinoma MDA MB 361 and colon carcinoma WiDr cells (70- to 450-fold) than was previously observed (19- to 27-fold) with 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA). Prodrug 1 is the most effective antitumor agent in xenografts in mice inoculated with 100% stCPG2(Q)3-expressing MDA MB 361 cells, whereas prodrugs 2 and 3 are most effective when the percentage of stCPG2(Q)3-expressing cells is 50% or 10%. In nude mice bearing xenografts arising from inocula of 100% stCPG2(Q)3-expressing WiDr cells, prodrug 2 is the most effective antitumor agent. All three of the prodrugs produced histological evidence of substantial bystander cell killing in WiDr xenografts in which only 10% or 50% of the cells inoculated were expressing stCPG2(Q)3. We conclude that all three of the prodrugs are more effective therapeutically with stCPG2(Q)3 than is the previously described prodrug CMDA and, also, that the optimal choice of prodrug varies among different tumor types and that prodrugs, optimized for their bystander effect, are effective when only low percentages of cells in a tumor express CPG2.
AuthorsFrank Friedlos, Lawrence Davies, Ian Scanlon, Lesley M Ogilvie, Janet Martin, Stephen M Stribbling, Robert A Spooner, Ion Niculescu-Duvaz, Richard Marais, Caroline J Springer
JournalCancer research (Cancer Res) Vol. 62 Issue 6 Pg. 1724-9 (Mar 15 2002) ISSN: 0008-5472 [Print] United States
PMID11912146 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Prodrugs
  • Glutamic Acid
  • beta-Galactosidase
  • gamma-Glutamyl Hydrolase
Topics
  • Animals
  • Antineoplastic Agents (pharmacokinetics, pharmacology)
  • Breast Neoplasms (drug therapy, genetics, metabolism, therapy)
  • Colorectal Neoplasms (drug therapy, genetics, metabolism, therapy)
  • Female
  • Genetic Therapy (methods)
  • Glutamic Acid (analogs & derivatives)
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Prodrugs (pharmacokinetics, pharmacology)
  • Transfection
  • Xenograft Model Antitumor Assays
  • beta-Galactosidase (genetics, metabolism)
  • gamma-Glutamyl Hydrolase (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: